Working… Menu
Trial record 2 of 2 for:    22047562 [PUBMED-IDS]

Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02438410
Recruitment Status : Recruiting
First Posted : May 8, 2015
Last Update Posted : November 12, 2018
Information provided by (Responsible Party):
Darrell S. Pardi, M.D., Mayo Clinic

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : December 2020
Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflammatory Bowel Diseases 1995;1:48-63.
Brandse J.F. MWM, de Bruyn J., Wolbink GJ., Lowenberg M., Ponsioen C., van den Brink G.R., D'Haens G.R. Fecal Loss of Infliximab As a Cause of Lack of Response in Severe Inflammatory Bowel Disease. Gastroenterology May 2013;144:S-36.